Every round on record, with the sources behind each and the investors on them.
A Toronto fertility company that sells subscription reproductive-health supplements and at-home test kits for women and men
birdandbe.comToronto, CanadaHealthtechFounded 2019
13 sources · checked 1 time, last 10d ago
Axios specifically identifies the financing as Series A; the company release and Fortune describe it generically as funding. The company release is used for the $13M amount and syndicate.
Publication audit: $13 million is includes secondary, not this round's money: "Bird&Be CEO Samantha Diamond told BetaKit in an email that the round closed in August and included a small amount of secondary issuances." (https://betakit.com/birdbe-raises-13-million-usd-series-a-for-fertility-support-platform)
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $13M incl. secondary | 2026-09-22 | BDC Thrive, BFG Partners | No recent discussion |
13 sources · checked 1 time, last 10d ago [ VERIFIED · CORRECTED ] read against 4 of 13 sources
Axios specifically identifies the financing as Series A; the company release and Fortune describe it generically as funding. The company release is used for the $13M amount and syndicate. Publication audit: $13 million is includes secondary, not this round's money: "Bird&Be CEO Samantha Diamond told BetaKit in an email that the round closed in August and included a small amount of secondary issuances." (https://betakit.com/birdbe-raises-13-million-usd-series-a-for-fertility-support-platform) | ||||
2 people on 7 outlets
Found on X with Firecrawl search
Bird&Be makes doctor-formulated fertility supplements and at-home reproductive-health tests for people with eggs and sperm, supporting fertility, pregnancy, and postpartum care.
Infertility affects about one in six people, male factors are involved in up to half of cases, and access to fertility specialists is limited; Bird&Be addresses that gap with products and education for both partners before and alongside clinic care. The company says it has grown into an eight-figure brand with nearly 100% year-over-year growth, 75% of revenue from subscriptions, and hundreds of thousands of people supported, while the new funding is aimed at clinical research, product development, and wider retail and clinical access.